Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| OCTRI #933 | Other Identifier | Oregon Health and Sciences University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to identify how certain parts of the brain that help control body weight respond to an infusion of hormones called leptin and amylin.
Following an overnight fast, subjects will undergo fMRI measurements of the hypothalamus, brainstem and whole brain during an infusion of either normal saline, pramlintide, leptin, or the combination leptin and pramlintide.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1- Normal Saline | Placebo Comparator | 4.7 mls normal saline IV bolus |
|
| 2 Metreleptin | Active Comparator | IV Leptin bolus |
|
| 3 Pramlintide | Active Comparator | IV Pramlintide bolus at Timpoint +0 and +30 minutes |
|
| 4 Leptin plus Pramlintide | Active Comparator | leptin and pramlintide IV bolus injection at timpoints 0 and +30 minutes |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pramlintide (Amylin) | Drug | 4.7 mls of Amylin 15mcg/ml IV bolus. |
|
| Measure | Description | Time Frame |
|---|---|---|
| To measure the fMRI response in the hypothalamus and brainstem, and whole brain, to intravenous leptin, pramlintide, combination leptin and pramlintide, and saline control. | measurements at each study time are include fMRI, blood draws and Visual Analog Score. | over 90 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Timed blood samples during infusion will establish the time course for peak levels of infused hormones as well as detectable changes in insulin and glucose levels. | Blood samples are taken every 5 minutes from Timepoint +0 to Timepoint +60 and again one time at Timepoint +90 | over 90 minutes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Those with a major medical illness or who require prescription medication, including: cancer, coronary artery disease, hypertension, and diabetes.
Subjects taking psychiatric or centrally-acting (CNS) medications or who are diagnosed with a psychiatric or neurological illness, including:
Exercise > 30 minutes, 3 times a week
Alcohol consumption > 2 drinks / day
Weight > 350 lbs (159 kg) (weight limit for MR machine)
Illicit drug use
Pregnancy
Extreme dietary habits as determined by a GCRC nutritionist: very high or low dietary carbohydrate or fat intakes
Those with a contraindication to exposure to strong magnetic fields: presence of metal in the body such as body piercing, shrapnel, cardiac pacemakers or aneurysm clips
Those with claustrophobia
Anaphylaxis and known hypersensitivity to E. coli-derived proteins
Allergies or contraindications to metreleptin or pramlintide
Renal or hepatic impairment
Women who are lactating
Tobacco use
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jonathan Q. Purnell, M.D. | OHSU - Center for the Study of Weight Regulation | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oregon Health & Science University | Portland | Oregon | 97239 | United States |
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C105254 | pramlintide |
| D058228 | Islet Amyloid Polypeptide |
| D000077330 | Saline Solution |
| D020738 | Leptin |
| ID | Term |
|---|---|
| D010187 | Pancreatic Hormones |
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo (Normal Saline) | Drug | 4.7 mls normal saline IV bolus x1 |
|
|
| 2 Metreleptin | Drug | Receive .06mg/kg of metreleptin IV bolus x1 |
|
|
| Leptin plus Pramlintide | Drug | receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes. |
|
|
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D058227 | Amyloidogenic Proteins |
| D000682 | Amyloid |
| D011506 | Proteins |
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
| D054392 | Adipokines |
| D036341 | Intercellular Signaling Peptides and Proteins |
| D001685 | Biological Factors |